You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
  1. W Poewe
  1. Universitätsklinik für Neurologie, Universität Innsbruck, Anichstraβe 35, A-6020 Innsbruck, Austria
  1. Correspondence to: 
 Dr W Poewe; 
 Werner.Poewe{at}uibk.ac.at

https://doi.org/10.1136/jnnp.72.4.430

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinically appropriate conversion factor may be less than three

    The issue of apparently different potencies of the two available formulations of botulinum toxin type A—Dysport and Botox—has continued to perplex clinicians for more than a decade. Empirically chosen doses expressed in mouse units in different series and different indications reported in the literature seemed to differ by factors of three to six.1,2 To date only two randomised controlled studies have tried to answer the question of what the correct conversion factor yielding bioequivalence should be. One was conducted in previously untreated patients with blepharospasm or hemifacial spasm and found a bioequivalence ratio of Botox to Dysport of 1:4 with duration of effect as …

    View Full Text

    Footnotes

    • Conflict of interest: WP has been reimbursed by Allergen Inc, the manufacturer of Botox and IPSEN, the manufacturer of Dysport, for speaking at conferences or educational courses. His department has also received grants from both.